In other drug safety news, FDA has announced the selection of Gerald J. Dal Pan, MD, MHS, as director, Office of Drug Safety in the Center for Drug Evaluation and Research (CDER). Dr Dal Pan, selected from a strong field of candidates as part of a nationwide search, will lead the agency's post-marketing drug safety program.
In other drug safety news, FDA has announced the selection of Gerald J. Dal Pan, MD, MHS, as director, Office of Drug Safety in the Center for Drug Evaluation and Research (CDER). Dr Dal Pan, selected from a strong field of candidates as part of a nationwide search, will lead the agency's post-marketing drug safety program.
"As part of our continuing commitment to drug safety and risk communication, we conducted a broad search for a candidate to lead our initiatives in this area," said Steven Galson, MD, CDER director. "Dr Dal Pan's extensive academic training and his practical experience in clinical medicine, drug development, and public health and risk management, coupled with his strong and vocal leadership within FDA, make him eminently qualified to take on the challenge of leading this vitally important office."
Prior to joining CDER, Dr Dal Pan directed clinical research, including clinical trial design and interpretation of clinical data, for Guilford Pharmaceuticals and HHI, LLC, Clinical Research and Statistical Services. He served on the faculty at Johns Hopkins University School of Medicine, where he conducted clinical research in addition to teaching medical students. He continues there as a part-time assistant professor in the Department of Neurology.
In addition to announcing the appointment of the new director of Drug Safety, as part of his annual State of CDER address to employees, Dr Galson outlined a proposed CDER reorganization to better align staff functions with CDER's goals and FDA's public health mission.
The goals of the proposed reorganization include:
"I am confident that these changes will lead to greater improvements in regulatory and drug development science and in how we evaluate and ensure the safety and efficacy of the products we regulate, and will result in greater protections for patients and consumers who depend on us every day," Dr Galson said.
Specific organizational changes were scheduled to be announced soon at press time; CDER leaders said they planned to implement them over the next 6 months.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More